Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1979 1
1980 2
1981 4
1983 5
1984 3
1985 3
1986 2
1987 7
1988 3
1989 4
1990 6
1991 2
1992 4
1993 5
1994 6
1995 3
1996 10
1997 7
1998 7
1999 15
2000 14
2001 16
2002 14
2003 8
2004 11
2005 21
2006 14
2007 25
2008 24
2009 34
2010 39
2011 35
2012 55
2013 60
2014 75
2015 72
2016 87
2017 102
2018 114
2019 127
2020 152
2021 199
2022 197
2023 213
2024 86

Text availability

Article attribute

Article type

Publication date

Search Results

1,659 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for median pf
Search for Medina PF instead (1 results)
Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group. Vermorken JB, et al. N Engl J Med. 2007 Oct 25;357(17):1695-704. doi: 10.1056/NEJMoa071028. N Engl J Med. 2007. PMID: 17960012 Free article. Clinical Trial.
RESULTS: A total of 358 patients underwent randomization, with 177 assigned to the TPF group and 181 to the PF group. At a median follow-up of 32.5 months, the median progression-free survival was 11.0 months in the TPF group and 8.2 months in the PF g …
RESULTS: A total of 358 patients underwent randomization, with 177 assigned to the TPF group and 181 to the PF group. At a median …
Macrophages in lung fibrosis.
Ogawa T, Shichino S, Ueha S, Matsushima K. Ogawa T, et al. Int Immunol. 2021 Nov 25;33(12):665-671. doi: 10.1093/intimm/dxab040. Int Immunol. 2021. PMID: 34270737 Free PMC article. Review.
Idiopathic PF, the cause of which is unknown, has a poor prognosis with a median survival of 2-4 years after diagnosis. ...In particular, clinical and basic research findings examining the roles of macrophages suggest that they may be pivotal regulators of PF …
Idiopathic PF, the cause of which is unknown, has a poor prognosis with a median survival of 2-4 years after diagnosis. ...In …
Center median-parafascicular complex and pain control. Review from a neurosurgical perspective.
Weigel R, Krauss JK. Weigel R, et al. Stereotact Funct Neurosurg. 2004;82(2-3):115-26. doi: 10.1159/000079843. Epub 2004 Jul 15. Stereotact Funct Neurosurg. 2004. PMID: 15305084 Review.
The center median-parafascicular (CM-Pf) complex, which constitutes the major portion of the intralaminar thalamus in man, has long been known to be involved in the processing of pain under normal and pathological conditions. ...Single-unit recordings from the CM- …
The center median-parafascicular (CM-Pf) complex, which constitutes the major portion of the intralaminar thalamus in man, has …
Amelioration of inflammatory myopathies by glucagon-like peptide-1 receptor agonist via suppressing muscle fibre necroptosis.
Kamiya M, Mizoguchi F, Yasuda S. Kamiya M, et al. J Cachexia Sarcopenia Muscle. 2022 Aug;13(4):2118-2131. doi: 10.1002/jcsm.13025. Epub 2022 Jun 30. J Cachexia Sarcopenia Muscle. 2022. PMID: 35775116 Free PMC article.

RESULTS: GLP-1R was expressed on the inflamed muscle fibres of PM and CIM. The treatment of CIM with PF1801 in monotherapy (PF) or in combination with PSL (PF + PSL) suppressed CIM-induced muscle weakness (grip strength, mean SD (g); PF 227 6.0 (P < 0.01),

…
RESULTS: GLP-1R was expressed on the inflamed muscle fibres of PM and CIM. The treatment of CIM with PF1801 in monotherapy (PF) or in …
The mechanism of gut-lung axis in pulmonary fibrosis.
Dong Y, He L, Zhu Z, Yang F, Ma Q, Zhang Y, Zhang X, Liu X. Dong Y, et al. Front Cell Infect Microbiol. 2024 Feb 1;14:1258246. doi: 10.3389/fcimb.2024.1258246. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38362497 Free PMC article. Review.
Its characteristics include short median survival, high mortality rate, and limited treatment effectiveness. ...The study of the gut-lung axis and PF is still in its early stages. This review systematically summarizes the mechanisms of PF related to the gut-l …
Its characteristics include short median survival, high mortality rate, and limited treatment effectiveness. ...The study of the gut- …
Rationale for targeting the thalamic centre-median parafascicular complex in the surgical treatment of Parkinson's disease.
Kerkerian-Le Goff L, Jouve L, Melon C, Salin P. Kerkerian-Le Goff L, et al. Parkinsonism Relat Disord. 2009 Dec;15 Suppl 3:S167-70. doi: 10.1016/S1353-8020(09)70807-7. Parkinsonism Relat Disord. 2009. PMID: 20082982 Review.
The thalamic centre median-parafascicular complex (CM/Pf), a main input and output station of the basal ganglia, is attracting increasing interest in the field of movement disorders, including Parkinson's disease (PD). CM/Pf undergoes partial neurodegeneratio …
The thalamic centre median-parafascicular complex (CM/Pf), a main input and output station of the basal ganglia, is attracting …
Pharmacokinetics/Pharmacodynamics of Caspofungin in Plasma and Peritoneal Fluid of Liver Transplant Recipients.
Pressiat C, Ait-Ammar N, Daniel M, Hulin A, Botterel F, Levesque E. Pressiat C, et al. Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0118721. doi: 10.1128/AAC.01187-21. Epub 2021 Oct 18. Antimicrob Agents Chemother. 2022. PMID: 34662185 Free PMC article.
All of the patients included were monitored weekly for Candida colonization and for Candida infections. Twenty patients were included. The median daily dose of caspofungin was 0.81 mg/kg. Plasma (n = 395) and PF (n = 50) concentrations at steady state were available …
All of the patients included were monitored weekly for Candida colonization and for Candida infections. Twenty patients were included. The …
MiRNA, a New Treatment Strategy for Pulmonary Fibrosis.
Liu Y, Nie H, Ding Y, Hou Y, Mao K, Cui Y. Liu Y, et al. Curr Drug Targets. 2021;22(7):793-802. doi: 10.2174/1874609813666200928141822. Curr Drug Targets. 2021. PMID: 32988351 Review.
Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a median survival of 2-4 years after diagnosis. ...Therefore, this review will set out the latest application of miRNAs to provide a new …
Pulmonary fibrosis (PF) is the most common chronic, progressive interstitial lung disease, mainly occurring in the elderly, with a …
Latest progress on the molecular mechanisms of idiopathic pulmonary fibrosis.
Fang Y, Tian J, Fan Y, Cao P. Fang Y, et al. Mol Biol Rep. 2020 Dec;47(12):9811-9820. doi: 10.1007/s11033-020-06000-6. Epub 2020 Nov 23. Mol Biol Rep. 2020. PMID: 33230784 Review.
Idiopathic pulmonary fibrosis (IPF) is a serious life-threatening lung disease, and the median survival period of PF patients after diagnosis is only 2.5-3.5 years. ...It is important to understand the cellular and molecular mechanisms of PF comprehensively a …
Idiopathic pulmonary fibrosis (IPF) is a serious life-threatening lung disease, and the median survival period of PF patients …
Radiology Profile as a Potential Instrument to Differentiate Between Posterior Fossa Ependymoma (PF-EPN) Group A and B.
Yonezawa U, Karlowee V, Amatya VJ, Takayasu T, Takano M, Takeshima Y, Sugiyama K, Kurisu K, Yamasaki F. Yonezawa U, et al. World Neurosurg. 2020 Aug;140:e320-e327. doi: 10.1016/j.wneu.2020.05.063. Epub 2020 May 16. World Neurosurg. 2020. PMID: 32428725

In the PF-EPN-A group, the progression-free survival median value was 32.6 months, and the overall survival median was 96.9 months. In contrast, PFS in PF-EPN-B did not reach a median value (P < 0.05) and all the patients were alive (P < 0

…
In the PF-EPN-A group, the progression-free survival median value was 32.6 months, and the overall survival median was …
1,659 results